- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.10. | Ondine Biomedical - Topline Results Significant in Steriwave ICU Study | 4 | RNS | ||
| 02.10. | Ondine Biomedical - Cambridge's Papworth Hospital Pilots Steriwave | 1 | RNS | ||
| ONDINE BIOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 26.09. | UK Stock Market News: Pennon, Seeing Machines, Ondine | 6 | The Armchair Trader | ||
| 26.09. | Ondine Biomedical - Ondine Biomedical Continues Growth in H1 2025 | 1 | RNS | ||
| 23.09. | Ondine Biomedical - Steriwave Now Protecting Patients with Cancer | - | RNS | ||
| 19.09. | Ondine Biomedical - Notice of Interim Results & Investor Presentation | - | RNS | ||
| 18.09. | Ondine reports 70% reduction in surgical site infections with Steriwave | 2 | Investing.com | ||
| 18.09. | Ondine: Steriwave senkt postoperative Wundinfektionen um 70 % | 2 | Investing.com Deutsch | ||
| 18.09. | Ondine Biomedical - Ondine Presents Major Economic Benefits at ICPIC | - | RNS | ||
| 15.09. | Ondine Biomedical - Steriwave proven to be effective against C Auris | - | RNS | ||
| 12.09. | Ondine Biomedical - Grant of Options | - | RNS | ||
| 10.09. | Ehemaliger Präsident Fox wirbt auf CNBC für Desinfektionstechnologie von Ondine | 2 | Investing.com Deutsch | ||
| 10.09. | Ondine's nasal disinfection technology featured on CNBC program | 1 | Investing.com | ||
| 10.09. | Ondine Biomedical - Steriwave Featured on CNBC's Worldwide Exchange | - | RNS | ||
| 08.09. | Ondine Biomedical - Notification of major holdings - hInsight | - | RNS | ||
| 04.09. | Pentwater Capital Management increases stake in Ondine Biomedical | 3 | Investing.com | ||
| 04.09. | Pentwater Capital Management stockt Beteiligung an Ondine Biomedical auf | 2 | Investing.com Deutsch | ||
| 04.09. | Ondine Biomedical: Großaktionärin Carolyn Cross reduziert Stimmrechtsanteil auf 23,01 % | 1 | Investing.com Deutsch | ||
| 04.09. | Carolyn Cross reduces stake in Ondine Biomedical to 23% | 1 | Investing.com | ||
| 04.09. | Robert Cross increases stake in Ondine Biomedical to over 7% | 1 | Investing.com |
1 2 3 Weiter >>
57 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 71,70 | +0,20 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| PASITHEA THERAPEUTICS | 1,470 | +52,33 % | Pasithea Therapeutics Shares Surge Nearly 39% After $60 Mln Equity Raise | ||
| ARCELLX | 72,71 | -0,74 % | CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting | ||
| ADMA BIOLOGICS | 19,180 | +0,21 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| QIAGEN | 41,125 | -0,77 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 195,96 | +3,94 % | Praxis Precision Medicines, Inc.: Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting | ||
| DYNE THERAPEUTICS | 21,910 | +3,50 % | Dyne Therapeutics: Bernstein hebt Kursziel wegen günstigem Risiko-Ertrags-Verhältnis an | ||
| HARMONY BIOSCIENCES | 35,290 | -0,76 % | Harmony Biosciences stock maintains Buy rating at H.C. Wainwright on positive study results | ||
| ARCUTIS BIOTHERAPEUTICS | 30,650 | -1,00 % | Mizuho raises Arcutis Biotherapeutics stock price target on strong Zoryve sales | ||
| RECURSION PHARMACEUTICALS | 4,630 | +4,99 % | Recursion Pharmaceuticals registriert Aktienpaket für Wiederverkauf durch Tempus AI | ||
| COGENT BIOSCIENCES | 40,250 | -0,35 % | Will Cogent Biosciences' (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So | ||
| DAY ONE BIOPHARMACEUTICALS | 9,490 | +0,85 % | Day One Biopharmaceuticals stock maintains Buy rating at H.C. Wainwright | ||
| MINERALYS THERAPEUTICS | 43,110 | -0,58 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) | ||
| SUMMIT THERAPEUTICS | 17,900 | +0,45 % | Summit Therapeutics to Present at Upcoming Investor Conferences | Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 84,12 | +0,55 % | Inhibrx Biosciences auf Rekordhoch: Aktie erreicht 87,4 US-Dollar trotz Warnsignalen |
ONDINE BIOMEDICAL INC CDIS gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,002 (+1,92 %) liegt der Kurs bei 0,106 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ONDINE BIOMEDICAL INC CDIS finden Sie auf Wallstreet Online.